WO1996003157A1 - Systeme ameliore permettant de desinfecter des lentilles de contact a l'eau oxygenee - Google Patents

Systeme ameliore permettant de desinfecter des lentilles de contact a l'eau oxygenee Download PDF

Info

Publication number
WO1996003157A1
WO1996003157A1 PCT/US1995/008929 US9508929W WO9603157A1 WO 1996003157 A1 WO1996003157 A1 WO 1996003157A1 US 9508929 W US9508929 W US 9508929W WO 9603157 A1 WO9603157 A1 WO 9603157A1
Authority
WO
WIPO (PCT)
Prior art keywords
die
hydrogen peroxide
solution
neutralizing agent
neutralization component
Prior art date
Application number
PCT/US1995/008929
Other languages
English (en)
Inventor
Masood Chowhan
Jaya Gautam
Original Assignee
Alcon Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories, Inc. filed Critical Alcon Laboratories, Inc.
Priority to AU31000/95A priority Critical patent/AU3100095A/en
Priority to EP95926711A priority patent/EP0773799A1/fr
Publication of WO1996003157A1 publication Critical patent/WO1996003157A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A61L12/12—Non-macromolecular oxygen-containing compounds, e.g. hydrogen peroxide or ozone
    • A61L12/124—Hydrogen peroxide; Peroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A61L12/12—Non-macromolecular oxygen-containing compounds, e.g. hydrogen peroxide or ozone
    • A61L12/124—Hydrogen peroxide; Peroxy compounds
    • A61L12/126—Hydrogen peroxide; Peroxy compounds neutralised with catalase or peroxidase

Definitions

  • the present invention relates to the field of ophthalmology. More particularly, the invention is directed to compositions and methods for disinfecting contact lenses.
  • the systems most frequently utilized involve the use of: 1) heat; 2) hydrogen peroxide; or 3) a chemical agent other than hydrogen peroxide.
  • the present invention is directed to the provision of an improved hydrogen peroxide disinfection system.
  • peroxides are very toxic to the cornea of the eye. Consequently, if peroxides are not completely removed from the disinfected contact lenses prior to reinsertion of the lenses in the eyes, severe ocular irritation can result. This problem has required special systems for ensuring that all of the peroxide is neutralized following disinfection of the lenses.
  • United States Patent No. 3,912,451 describes the use of a transition metal, such as platinum, as a catalyst to accelerate the decomposition of hydrogen peroxide.
  • a transition metal such as platinum
  • This type of system has been marketed for several years under the name AOSept® (CibaVision).
  • AOSept® CibaVision
  • the system is relatively expensive, and the platinum disk used as the neutralizing component is susceptible to being contaminated by proteins or other debris. Such contamination may effectively destroy or limit the ability of the disk to neutralize hydrogen peroxide.
  • catalase to neutralize hydrogen peroxide enzymatically is described in United States Patent No. 4,585,488.
  • This type of system has also been utilized in commercial hydrogen peroxide disinfection systems, such as the Lensan® system marketed by CibaVision.
  • the prior catalase- based systems are rather inconvenient to use, because once the lens is disinfected, it is necessary to remove it from the hydrogen peroxide solution and place it in a separate solution containing catalase.
  • the prior delayed-release catalase tablets do not provide for preservation of the solution containing the contact lenses once the hydrogen peroxide is neutralized. More specifically, the prior art tablets do not include an agent having sustained antimicrobial activity, and consequently are not capable of preventing recontamination of the lens by microorganisms during storage of the lens in the neutralized solution following the disinfection and neutralization steps. Viable microorganisms have been found to be present in 30 to 70% of contact lens cases. The risk of recontamination is therefore significant. Such recontamination of the lenses may be highly detrimental to the vision of the patient, particularly when the regrowth involves Pseudomonas aeruginosa.
  • the present invention is based on the discovery that the inclusion of boric acid and glycine in a composition containing a hydrogen peroxide neutralizing agent, such as catalase, results in a superior hydrogen peroxide disinfection system.
  • a hydrogen peroxide neutralizing agent such as catalase
  • the system is believed to be superior to prior systems in several respects, but the ability of the system to ensure that the neutralizing solution does not become contaminated by microorganisms, particularly pathogenic microorganisms such as Pseudomonas aeruginosa, is considered to be one of the most significant improvements provided by the present invention.
  • the hydrogen peroxide disinfecting system of the present invention also contributes to the removal of deposits from contact lenses and helps to prevent deposits from forming.
  • Contact lenses accumulate deposits which are predominantly proteins and lipids.
  • Divalent cations present in tear films, such as calcium and magnesium, may also become a part of the deposits, and thereby form complex deposits which are even more difficult to remove.
  • formulations for cleaning contact lenses typically contain a chelating agent, such as EDTA, in order to prevent the formation of such deposits.
  • EDTA EDTA
  • the presence of glycine in the hydrogen peroxide disinfection system of the present invention helps to reduce the formation of complex deposits involving divalent cations. This is an incidental, but significant advantage of the invention. Other advantages of the present invention will be apparent to those skilled in the art based on d e description of the preferred embodiments of the invention presented below.
  • the improved hydrogen peroxide disinfecting system of the present invention includes a disinfection component and a neutralization component.
  • the disinfection component is a solution containing hydrogen peroxide in a concentration of from about 0.05 to about 5.0 percent by weight/volume ("w/v%"). The most preferred concentration is about 3 w/v%.
  • the hydrogen peroxide solution may be formed by dissolving a solid peroxide, such as sodium perborate or persulfate, in an aqueous solution.
  • the disinfection component may therefore be provided in the form of a tablet, granules or powder containing a solid peroxide which is dissolved in an aqueous solution at the time of use.
  • the use of a hydrogen peroxide solution as the disinfection component is preferred.
  • the neutralization component is preferably formulated as a tablet, granules or powder, but may also be formulated as a liquid.
  • the neutralization component includes a hydrogen peroxide neutralizing agent, boric acid and glycine.
  • the neutralizing agents which may be utilized in the present invention include catalase, sodium pyruvate and sodium thiosulfate.
  • the preferred hydrogen peroxide neutralizing agent is catalase.
  • the most preferred neutralization component of the present invention is a delayed release tablet which contains catalase, boric acid and glycine.
  • the neutralization component will be utilized in an amount sufficient to totally decompose all hydrogen peroxide remaining after disinfection of the lenses.
  • the amount of neutralizing agent required for this purpose will vary depending on various factors, such as the peroxide concentration, the neutralizing agent selected, and the length of time in which the neutralization step is to be completed.
  • the most preferred neutralizing agent, catalase will generally be utilized in an amount of from about 500 to about 10,000 activity units, preferably about 1,000 to about 5,000 activity units. The latter range is particularly appropriate for neutralization of a 3.0 w/v% hydrogen peroxide solution by catalase derived from a mammalian source.
  • Sodium pyruvate will generally be utilized in an amount of from about 100 milligrams (“mg") to about 1 gram ("g"), and sodium thiosulfate will generally be utilized in an amount of from about 140 mg to about 1.4 g.
  • the amounts of other neutralizing agents required can be readily determined by those skilled in the art.
  • the foregoing amounts of neutralizing agents may be utilized to neutralize 10 milliliters ("ml") of a 0.3 to 3.0 w/v% hydrogen peroxide solution.
  • the neutralization component is preferably formulated so as to provide for delayed release of the neutralizing agent into the hydrogen peroxide disinfecting solution.
  • the delayed release of the neutralizing agent can be achieved by various means, such as film-coated tablets, tablets made by compressing film-coated granules, matrix tablets, dry powder compression tablets, layered tablets, gelatin capsules filled with powder or granules, and gelatin capsules filled with coated granules.
  • a tablet wherein the neutralizing agent is contained in an inner core surrounded by a layer of retardant material is preferred.
  • the neutralization component contains boric acid and glycine.
  • Boric acid serves as an antimicrobial agent when dissolved in the hydrogen peroxide disinfecting solution.
  • the antimicrobial activity of boric acid helps to ensure that the solution containing the disinfected contact lenses does not become contaminated with microbes following neutralization of the hydrogen peroxide.
  • the boric acid serves as an antimicrobial preservative.
  • the glycine also contributes to this aspect of the invention. More specifically, the glycine produces a significant enhancement in the antimicrobial activity of the boric acid.
  • the glycine helps to remove and or prevent complex deposits of proteins and lipids involving divalent cations. Boric acid and glycine will generally be utilized in amounts of from about 0.1 to about 3.0 w/v%.
  • the boric acid and glycine also increase the bulk and density of the neutralization component. It is highly desirable for the neutralization component to be more dense than the hydrogen peroxide solution in which the contact lenses are contained, so that the neutralizing agent will be present in the bottom of the container. If the neutralization component is not relatively dense, it will tend to float in the hydrogen peroxide solution, particularly if the solution becomes effervescent when the neutralizing agent begins to dissolve. This is potentially a problem, since the neutralizing agent may not be adequately dispersed in the hydrogen peroxide solution to neutralize all of the hydrogen peroxide if the tablet or capsule only releases d e neutralizing agent in the upper portion of the container.
  • the neutralization component of the present invention therefore contains boric acid and glycine in amounts sufficient to ensure that me density of this component is greater tiian that of the hydrogen peroxide solution in which it is to be placed.
  • boric acid and glycine are therefore preferably included in die inner core of a multi-layer tablet or in the coated particles of a matrix tablet, along with die neutralizing agent.
  • the neutralization component of die present invention will preferably also include one or more coating agents to retard (i.e., delay) the release of the neutralizing agents in solution.
  • coating agents can be generally described as being cellulose derivatives, such as hydroxy propyl methyl cellulose ("HPMC"), or synd etic polymers, such as polyacrylic acid polymers. These polymers are commercially available.
  • HPMC is available from Aqualon under the name "KlucelTM” and polyacrylic acid polymers are available from Rohm Tech, Inc. under the name "EudragitTM”.
  • the amount of coating agent required may vary considerably depending on d e particular coating agent selected and the form of d e neutralization component (i.e., tablets, or encapsulated granules or powders).
  • One or more coating agents will be utilized in an amount sufficient to delay die release of die neutralizing agent in die hydrogen peroxide solution until disinfection of die contact lenses is either completed or substantially completed.
  • the neutralization component may also contain miscellaneous ingredients, such as antifoaming agents (e.g., PluronicTM L61, a nonionic surfactant; simethicone; or tributyl phosphate), tonicity-adjusting agents (e.g., mannnitol) and buffers (e.g., phosphates, borates or citrates).
  • antifoaming agents e.g., PluronicTM L61, a nonionic surfactant; simethicone; or tributyl phosphate
  • tonicity-adjusting agents e.g., mannnitol
  • buffers e.g., phosphates, borates or citrates.
  • borate/polyol buffering system is preferred.
  • d e term "borate" shall refer to boric acid, salts of boric acid and other pharmaceutically acceptable borates, or combinations tiiereof.
  • polyol refers to any compound having at least two adjacent -OH groups which are not in trans configuration relative to each otiier.
  • the polyols can be linear or circular, substituted or unsubstituted, or mixtures thereof, so long as die resultant complex is water-soluble and pharmaceutically acceptable.
  • Such compounds include sugars, sugar alcohols, sugar acids and uronic acids.
  • Preferred polyols are sugars, sugar alcohols and sugar acids, including, but not limited to: mannitol, glycerin, propylene glycol and sorbitol.
  • Especially preferred polyols are mannitol and glycerin; mannitol is most preferred.
  • borate-polyol complexes in ophthalmic compositions is described in copending, commonly assigned United States Patent Application Serial No. 08/198,427 filed February 21, 1994, and in corresponding PCT International Application Number
  • PCT/US93/04226 International Publication Number WO 93/21903; the entire contents of die foregoing applications are hereby incorporated in the present specification by reference.
  • the above-described hydrogen peroxide disinfection system may be utilized to disinfect contact lenses in accordance witii techniques known to diose skilled in d e art. Such techniques generally involve placing the lenses in a hydrogen peroxide solution, adding a delayed-release neutralizing tablet to that solution, and then allowing die lenses to soak in die solution a length of time sufficient to disinfect the lenses and to neutralize die hydrogen peroxide.
  • the amount of time required to complete tiiis process may vary between different embodiments of die invention, but will generally be from about ten minutes to about two hours.
  • the neutralizing component of the above-described system is preferably provided as a delayed-release tablet for purposes of convenience, it is also possible to utilize die neutralization component of die present invention in otiier forms.
  • tiiis component can be formulated as conventional tablets or solutions which do not provide for delayed release of die neutralizing agent into solution.
  • die neutralization component is added to the hydrogen peroxide solution after disinfection is completed.
  • tiiese embodiments of die invention are somewhat less convenient, die principal benefits of die invention, particularly die preservative effect of die boric acid and glycine in die neutralizing solution, are retained.
  • the present invention are further illustrated by die following examples.
  • d e neutralization component is provided as a delayed release tablet, witii die neutralizing agent contained in an inner core of d e tablet along witii the boric acid and glycine.
  • the inner core may be prepared as follows. First, half of die boric acid is granulated by mixing with the surfactant (i.e., PluronicTM L61) in alcohol. The remainder of die boric acid is then combined widi die glycine and granulated by mixing with the povidone in alcohol. Botii of the granulated mixtures are dried overnight in an oven at approximately 50°C. The dried granules are tiien passed dirough a Fitz mill equipped widi a size 20 sieve. The catalase and sodium carbonate are then combined widi die sieved granules and blended for 30 minutes. The polyethylene glycol (i.e., PEG 3350) is dien added, and the resulting mixture is blended for 5 minutes. The mixture is tiien compressed into a tablet.
  • the surfactant i.e., PluronicTM L61
  • the outer layer may be formed by dissolving die HPMC (i.e., Klucel EF) in the purified water at 70°C, using constant stirring. After allowing die solution to cool to room temperature, it is filtered dirough a size 50 mesh. The filtered solution is then sprayed on die inner core tablet in small quantities, wid die inner core tablet being dried after each application of polymer.
  • HPMC i.e., Klucel EF
  • Example 2 Experiments were conducted to compare the antimicrobial activity of the hydrogen peroxide contact lens disinfection system of die present invention to that of other systems. The experiments involved five (5) different neutralizing components, all of which were formulated as delayed release tablets. The compositions of four of the tablets are shown below:
  • Formulations A and B represent examples of conventional neutralizing tablets containing catalase as the neutralizing agent and sodium chloride as a major excipient for tonicity adjustment.
  • Formulations C and D represent examples of the neutralization component of the present invention, wherein the sodium chloride has been replaced by boric acid and glycine.
  • the fiftii tablet utilized in die experiments was die UltraCareTM neutralizing tablet marketed by Allergan Optical. This tablet contains catalase and sodium chloride, and is otiierwise generally similar in composition to Formulations A and B above.
  • the antimicrobial activity of the above-described tablets was evaluated as follows. Each tablet was allowed to neutralize 10 ml of 3% hydrogen peroxide. Each of die neutralized solutions was then inoculated widi a titer of 1.0 x 10 3 microorganisms (i.e., Staph. aureus, Pseudomonas aeruginosa and Aspergillus niger). Samples of die solutions were taken at 6, 24 and 168 hours and die microbial population of die solutions were calculated based on tiiese samples. The results are presented below:
  • Pa Pseudomonas aeruginosa

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

On décrit des systèmes et procédés qui permettent de désinfecter des lentilles de contact avec des solutions d'eau oxygénée et reposent sur l'utilisation d'un moyen amélioré de neutraliser l'eau oxygénée après désinfection. La composante de neutralisation propre à l'invention contient un agent de neutralisation de l'eau oxygénée, de l'acide borique et de la glycine. Cette composante de neutralisation offre une activité antimicrobienne suffisante pour éviter une nouvelle contamination des lentilles avec des bactéries ou autres microbes pendant l'étape de neutralisation.
PCT/US1995/008929 1994-07-22 1995-07-17 Systeme ameliore permettant de desinfecter des lentilles de contact a l'eau oxygenee WO1996003157A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU31000/95A AU3100095A (en) 1994-07-22 1995-07-17 Improved system for disinfecting contact lenses with hydrogen peroxide
EP95926711A EP0773799A1 (fr) 1994-07-22 1995-07-17 Systeme ameliore permettant de desinfecter des lentilles de contact a l'eau oxygenee

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27913494A 1994-07-22 1994-07-22
US08/279,134 1994-07-22

Publications (1)

Publication Number Publication Date
WO1996003157A1 true WO1996003157A1 (fr) 1996-02-08

Family

ID=23067768

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/008929 WO1996003157A1 (fr) 1994-07-22 1995-07-17 Systeme ameliore permettant de desinfecter des lentilles de contact a l'eau oxygenee

Country Status (3)

Country Link
EP (1) EP0773799A1 (fr)
AU (1) AU3100095A (fr)
WO (1) WO1996003157A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2397538A1 (fr) * 2010-06-18 2011-12-21 Bausch & Lomb Incorporated Solution de peroxyde d'entretien de lentilles de contact
US9011932B2 (en) 2010-09-16 2015-04-21 Bausch & Lomb Incorporated Contact lens care system with peroxide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0142642A1 (fr) * 1983-08-25 1985-05-29 Barnes-Hind, Inc. Procédé et "kit" pour la neutralisation de H2O2 sur des lentilles de contact au moyen de sulfite de sodium
US4880601A (en) * 1985-09-27 1989-11-14 Laboratoires, P.O.S. Hydrogen peroxide disinfecting system for contact lenses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0142642A1 (fr) * 1983-08-25 1985-05-29 Barnes-Hind, Inc. Procédé et "kit" pour la neutralisation de H2O2 sur des lentilles de contact au moyen de sulfite de sodium
US4880601A (en) * 1985-09-27 1989-11-14 Laboratoires, P.O.S. Hydrogen peroxide disinfecting system for contact lenses

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2397538A1 (fr) * 2010-06-18 2011-12-21 Bausch & Lomb Incorporated Solution de peroxyde d'entretien de lentilles de contact
WO2011159364A1 (fr) * 2010-06-18 2011-12-22 Bausch & Lomb Incorporated Solution de soin pour lentilles de contact au peroxyde
JP2013531814A (ja) * 2010-06-18 2013-08-08 ボーシュ アンド ローム インコーポレイティド 過酸化物コンタクトレンズケア液
EP2638920A1 (fr) * 2010-06-18 2013-09-18 Bausch & Lomb Incorporated Solution de peroxyde d'entretien de lentilles de contact
AU2011265728B2 (en) * 2010-06-18 2013-09-19 Bausch & Lomb Incorporated Peroxide contact lens care solution
US8932646B2 (en) 2010-06-18 2015-01-13 Bausch & Lomb Incorporated Peroxide contact lens care solution
KR101842294B1 (ko) 2010-06-18 2018-03-26 보오슈 앤드 롬 인코포레이팃드 과산화물 콘택트 렌즈 관리 용액
US10130733B2 (en) 2010-06-18 2018-11-20 Bausch & Lomb Incorporated Peroxide contact lens care solution
US9011932B2 (en) 2010-09-16 2015-04-21 Bausch & Lomb Incorporated Contact lens care system with peroxide

Also Published As

Publication number Publication date
EP0773799A1 (fr) 1997-05-21
AU3100095A (en) 1996-02-22

Similar Documents

Publication Publication Date Title
EP0083820B1 (fr) Solutions désinfectantes pour lentilles de contact hydrophiles
US4863627A (en) Cleaning and/or disinfection of contact lenses
US5494937A (en) Saline solution for treating contact lenses
EP0110609B1 (fr) Traitement de stérilisation par le péroxyde hydrogène et neutralisation de quantités résiduelles de ce dernier
US3671545A (en) Polyvinylpyrrolidone-iodine compounds
US4775424A (en) Disinfecting and cleaning system for contact lenses
EP0371728B1 (fr) Solution ophtalmique aqueuse et son procédé de conservation
EP0458578B1 (fr) Double système redox pour la désinfection de lentilles de contact
JPH0254804B2 (fr)
JP2930412B2 (ja) コンタクトレンズ消毒用システム
US4490389A (en) Contact lens preserving solution containing ascorbic acid or salts thereof
US4880601A (en) Hydrogen peroxide disinfecting system for contact lenses
US4581379A (en) Contact lens preserving solution
EP0773799A1 (fr) Systeme ameliore permettant de desinfecter des lentilles de contact a l'eau oxygenee
US5589387A (en) Method for preventing the accumulation of inorganic deposits on contact lenses
JPH09206362A (ja) コンタクトレンズ用消毒洗浄組成物及びそれを用いたコンタクトレンズの消毒洗浄方法
IE920838A1 (en) Contact lens disinfecting compositions
US4581374A (en) Contact lens preserving solution
JPH06102474A (ja) コンタクトレンズ用剤組成物
TW201138865A (en) Dry-coated tablet for cleaning contact lens and formulation for contact lens cleaning containing the tablet, and method of cleaning contact lens
GB1566646A (en) Contact lens preserving solution
RU2098136C1 (ru) Композиция для разложения перекиси водорода, способ ее получения и способ дезинфекции линз

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995926711

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995926711

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1995926711

Country of ref document: EP